Michaël Vlemmix

Michaël is a Bio-Engineer (Cell & Gene Biotechnology) holding a Master in Management from the Antwerp Management School. He started his professional career in 2012 at Oxypoint, a medical device spin-off of the University of Antwerp. In February 2016, he switched to investment banking at KBC Securities as a Biotech/Healthcare analyst where he worked on initial public offerings and several other capital market transactions while providing coverage of the Benelux Biotech & Healthcare stocks.

Late 2017, Michaël joined the Gimv Health & Care team. Today he is representing Gimv on the board of directors of Precirix (Belgium) and SynOx (Ireland) while supporting several other portfolio companies.